

Press Release

## **Alkem Laboratories becomes first in India to launch semaglutide in single-shot pre-filled syringes at price starting INR350**

- *With this additional delivery format, Alkem aims to lower entry barriers to semaglutide treatment for patients*
- *Alkem had already launched semaglutide injection pens in March 2026*

**Mumbai, June 2, 2026:** Alkem Laboratories Ltd. (BSE: 539523, NSE: ALKEM, “Alkem” and its subsidiaries) today announced the launch of semaglutide in single-shot pre-filled syringes in multiple dose strengths at price starting INR350.

Alkem is the first company in India to introduce semaglutide in single-shot pre-filled syringe format, expanding treatment options for patients and lowering entry barriers with its affordable pricing. The ready-to-use single shot pre-filled syringe format offers enhanced access, and convenience.

The company has received approval from the Drugs Controller General of India (DCGI) to manufacture and market semaglutide pre-filled syringes for the management of Type 2 diabetes mellitus and obesity as an adjunct to diet and exercise.

In March 2026, Alkem had already launched semaglutide in pre-filled disposable and reusable injection pens format in the Indian market. The company has also received regulatory approval for semaglutide vials, which will be launched soon.

***Commenting on the development, Dr. Vikas Gupta, Chief Executive Officer, Alkem said, “Semaglutide has the potential to change how we manage metabolic disorders. With the launch of our pre-filled syringes, we are widening the choice available to doctors and patients, alongside the pen options we have already introduced. In India, where we are seeing a continuous rise in disease burden, offering multiple, practical drug delivery formats is an important step in helping more patients start and stay on the therapy.”***

Alkem remains committed to advancing high-quality, affordable medicines across key therapeutic areas and supporting better patient care in India.

--End--

### **About Alkem:**

Alkem Laboratories Ltd. is a leading Indian pharmaceutical company with a legacy of 50 years in providing high quality medicines to patients. It is the sixth-largest pharmaceutical company in the Indian market with a dominant position in the therapy areas of anti-infectives, gastrointestinal, pain management drugs and supplements. It also has a growing portfolio of products in chronic therapies such as diabetes, neurology, cardiology, dermatology and urology. It has 18 state-of-the-art manufacturing facilities and cutting-edge research and development (R&D) centres across India and the US to develop and manufacture generic formulations, active pharmaceutical ingredients (APIs) and biosimilars. Apart from India, the company has meaningful presence in the US, Latin America, Australia and several Asian countries. “Inspiring Healthier Lives” is at the core of the values and culture of the organisation and reinforces its steadfast commitment to global health improvement. For more information, please visit [www.alkemlabs.com](http://www.alkemlabs.com) and follow us on [LinkedIn](#), [Instagram](#), [Facebook](#).

### **Contacts**

#### **Media:**

Isha Trivedi

[alkemcorpcomm@alkem.com](mailto:alkemcorpcomm@alkem.com)

+91-98925 90003

#### **Investors:**

Purvi Shah

[purvi.shah@alkem.com](mailto:purvi.shah@alkem.com)

+91-84337 00890